These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32363945)

  • 1. Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan.
    Suzuki T; Fairburn-Beech J; Sato K; Kaise T
    Curr Med Res Opin; 2020 Jun; 36(6):1049-1057. PubMed ID: 32363945
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
    Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
    Suissa S; Dell'Aniello S; Ernst P
    Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S; Dell'Aniello S; Ernst P
    Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.
    Bogart M; Stanford RH; Laliberté F; Germain G; Wu JW; Duh MS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():343-352. PubMed ID: 30863037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan.
    Oga T; Mita C; Ito R; Requena G; Rothnie KJ; Noorduyn SG; Yuanita L; Yarita M
    Respir Investig; 2024 Jul; 62(4):685-694. PubMed ID: 38796907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
    Liao PA; Pan SW; Chen CY; Deng CY; Dong YH
    Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
    Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled corticosteroids with combination inhaled long-acting beta
    Tan DJ; White CJ; Walters JA; Walters EH
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD011600. PubMed ID: 27830584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
    Lane DC; Stemkowski S; Stanford RH; Tao Z
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1165-1172. PubMed ID: 30362922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
    Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.
    Ding B; Small M
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.